| Characteristic . | All Study Participants (n = 384) . | Data Available on Relapse Risk (n = 231) . | Data Not Available on Relapse Risk (n = 153) . |
|---|---|---|---|
| Age, y | 48.0 (35.0–58.0) | 50.0 (36.5–60.0) | 45 (33–54) |
| Women | 327 (85.2) | 195 (84.4) | 132 (86) |
| Smoking | |||
| Current | 104 (27.1) | 64 (27.7) | 40 (26.1) |
| Former | 90 (23.4) | 60 (26.0) | 30 (19.6) |
| Never | 190 (49.5) | 107 (46.3) | 83 (54.2) |
| Race | |||
| White | 359 (93.5) | 217 (93.9) | 142 (92.8) |
| Black | 3 (0.8) | 1 (0.4) | 2 (1.3) |
| Asian | 22 (5.7) | 13 (5.6) | 9 (5.9) |
| Active GO | 74 (19.3) | 43 (18.6) | 31 (20.3) |
| TPOAb, IU/mL | 128.0 (22.9–365.2) | 129.2 (26.6–379.9) | 124 (10.5–130.2) |
| TRAb, U/L | 7.0 (3.6–14.3) | 7.0 (3.7–13.6) | 7.1 (3.2–16.0) |
| FT4, pmol/L | 39.8 (28.3–58.8) | 39.3 (29.1–58.4) | 40.0 (23.5–59.4) |
| FT3, pmol/L | 15.2 (9.7–26.0) | 15.1 (10.2–25.4) | 16.1 (8.0–27.7) |
| Characteristic . | All Study Participants (n = 384) . | Data Available on Relapse Risk (n = 231) . | Data Not Available on Relapse Risk (n = 153) . |
|---|---|---|---|
| Age, y | 48.0 (35.0–58.0) | 50.0 (36.5–60.0) | 45 (33–54) |
| Women | 327 (85.2) | 195 (84.4) | 132 (86) |
| Smoking | |||
| Current | 104 (27.1) | 64 (27.7) | 40 (26.1) |
| Former | 90 (23.4) | 60 (26.0) | 30 (19.6) |
| Never | 190 (49.5) | 107 (46.3) | 83 (54.2) |
| Race | |||
| White | 359 (93.5) | 217 (93.9) | 142 (92.8) |
| Black | 3 (0.8) | 1 (0.4) | 2 (1.3) |
| Asian | 22 (5.7) | 13 (5.6) | 9 (5.9) |
| Active GO | 74 (19.3) | 43 (18.6) | 31 (20.3) |
| TPOAb, IU/mL | 128.0 (22.9–365.2) | 129.2 (26.6–379.9) | 124 (10.5–130.2) |
| TRAb, U/L | 7.0 (3.6–14.3) | 7.0 (3.7–13.6) | 7.1 (3.2–16.0) |
| FT4, pmol/L | 39.8 (28.3–58.8) | 39.3 (29.1–58.4) | 40.0 (23.5–59.4) |
| FT3, pmol/L | 15.2 (9.7–26.0) | 15.1 (10.2–25.4) | 16.1 (8.0–27.7) |
Data are presented as number (percentage) or median (interquartile range).
Abbreviations: FT3, free T3; FT4, free T4.
| Characteristic . | All Study Participants (n = 384) . | Data Available on Relapse Risk (n = 231) . | Data Not Available on Relapse Risk (n = 153) . |
|---|---|---|---|
| Age, y | 48.0 (35.0–58.0) | 50.0 (36.5–60.0) | 45 (33–54) |
| Women | 327 (85.2) | 195 (84.4) | 132 (86) |
| Smoking | |||
| Current | 104 (27.1) | 64 (27.7) | 40 (26.1) |
| Former | 90 (23.4) | 60 (26.0) | 30 (19.6) |
| Never | 190 (49.5) | 107 (46.3) | 83 (54.2) |
| Race | |||
| White | 359 (93.5) | 217 (93.9) | 142 (92.8) |
| Black | 3 (0.8) | 1 (0.4) | 2 (1.3) |
| Asian | 22 (5.7) | 13 (5.6) | 9 (5.9) |
| Active GO | 74 (19.3) | 43 (18.6) | 31 (20.3) |
| TPOAb, IU/mL | 128.0 (22.9–365.2) | 129.2 (26.6–379.9) | 124 (10.5–130.2) |
| TRAb, U/L | 7.0 (3.6–14.3) | 7.0 (3.7–13.6) | 7.1 (3.2–16.0) |
| FT4, pmol/L | 39.8 (28.3–58.8) | 39.3 (29.1–58.4) | 40.0 (23.5–59.4) |
| FT3, pmol/L | 15.2 (9.7–26.0) | 15.1 (10.2–25.4) | 16.1 (8.0–27.7) |
| Characteristic . | All Study Participants (n = 384) . | Data Available on Relapse Risk (n = 231) . | Data Not Available on Relapse Risk (n = 153) . |
|---|---|---|---|
| Age, y | 48.0 (35.0–58.0) | 50.0 (36.5–60.0) | 45 (33–54) |
| Women | 327 (85.2) | 195 (84.4) | 132 (86) |
| Smoking | |||
| Current | 104 (27.1) | 64 (27.7) | 40 (26.1) |
| Former | 90 (23.4) | 60 (26.0) | 30 (19.6) |
| Never | 190 (49.5) | 107 (46.3) | 83 (54.2) |
| Race | |||
| White | 359 (93.5) | 217 (93.9) | 142 (92.8) |
| Black | 3 (0.8) | 1 (0.4) | 2 (1.3) |
| Asian | 22 (5.7) | 13 (5.6) | 9 (5.9) |
| Active GO | 74 (19.3) | 43 (18.6) | 31 (20.3) |
| TPOAb, IU/mL | 128.0 (22.9–365.2) | 129.2 (26.6–379.9) | 124 (10.5–130.2) |
| TRAb, U/L | 7.0 (3.6–14.3) | 7.0 (3.7–13.6) | 7.1 (3.2–16.0) |
| FT4, pmol/L | 39.8 (28.3–58.8) | 39.3 (29.1–58.4) | 40.0 (23.5–59.4) |
| FT3, pmol/L | 15.2 (9.7–26.0) | 15.1 (10.2–25.4) | 16.1 (8.0–27.7) |
Data are presented as number (percentage) or median (interquartile range).
Abbreviations: FT3, free T3; FT4, free T4.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
